Analysing Patent Terms and Citations to Determine the Value of Gene Therapies
DOI:
https://doi.org/10.5912/jcb777Keywords:
1, gene therapies, 2, patent citations and 3, market value & capitalizationAbstract
Gene therapies hold great promise for treatment of diseases but so far their market authorisation has been limited. This paper describes the development of patented gene therapies in the sector of life sciences and health. It was found that the annual number of patented gene therapies increased significantly till the year 2005. A cluster analysis of gene therapies patented in 1995 shows that: a) more than eighty percent has been renewed for more than fifteen years (fifty three per cent till the maximum patent term) and b) fifty per cent of the patents have been licensed. There is a statistically significant correlation between the numbers of citations in future patent applications by third parties and the number of years of patent renewals.
A case study of the patent EP 0833934 of biotechnology start- up Crucell demonstrates that the number of citations by third companies to this patent even predicts the companies’ market capitalization. This research yielded evidence that the number of patent citations can be used as indicator to determine the value of gene therapies. Such information is of relevance for both the patentee and investors.
References
Torrance, A.W. (2014). Gene concepts, gene talk and gene patents. Miss. J. Of Science and Technology (2010), 11 (1), 157 - 191
Alberts, B., Johnson, A., Lewis, J. Raff, M. Roberts, K. and Walter, P. (2012). Molecular Biology of the Cell, Garland Science, p.
Editorial (1999). Nature (401), 517-8
Personal communication B. Leufkens, CBG MEB (2016)
Dutfield, G. (2006). DNA patenting: implications for public health research, WHO bulletin, 84 (5), 388- 392
Jensen, K. and Murray, F. (2005). Intellectual Property Landscape of the Human Genome. Science, 310 (5746), 239 - 240
Castle, D. ed. (2006). The role of Intellectual Property Rights in Biotechnology Innovation, Edward Elgar, Northampton, MA, USA p. 101- 152
Soini, S., Ayme, S., and Matthijs, G. (2008). Patenting and licensing in genetic testing: ethical, legal
and social issues, European Journal of Human Genetics, 16, 510 - 50
Regents of the University of California (2001). Recombinant DNA Research at UCSF and Commercial Application at Genentech, Boyer's UCSF Laboratory
Patzelt, H. and Brenner, T. eds. (2008). Handbook for bio tech entrepreneurs. Springer. New York, p.193- 207
Chapter 10
Zucker, L.G., Darby, M.R. and Amstrong, J.S. (2002). Commercializing Knowledge: University Science, Knowledge Capture and Firm Performance in Biotechnology, Management Science, 48 (1), 149 - 170
Zechendorf, B. (2011). Regional Biotechnology- The EU biocluster study, Journal of Commercial Biotechnology, 17, 209-217, http://doi.org/10.1057/jcb.2011.13
Pugatch, M.P., Torstensson, D. and Chu, R. (2012). Taking stock: How global biotechnology benefits from Intellectual Property Rights, Pugatch Consilium, 57 p.
OECD (2011). Intellectual Assets and Innovation, http://www.oecd-ilibrary.org/intellectual-assets-and-innovation
Gambardella, A., Harhoff, D. and Verspagen, B. (2008). The value of European patents. European Management Review 5, 69-84
Harhoff, D., Scherer, F.M. and Vopel, K. (2003). Citations, family size, opposition and the value of patent rights, Research Policy. 32, 1343- 1363
Harhoff, D., Narin, F., Sherer, F.M. and Vopel, K. (1999). Citation Frequency and the value of patented inventions. The Review of Economics and Statistics. 81 (3), 511-515, doi/10.1162/003465399558265
Magazzini, L. , Pammolli, F. And Riccaboni, M. (2008). Patent value and R&D Competion, DRUID Summer Conference Copenhagen
Hall, B.H, Jaffe, A. and Trajtenberg, M. (2005). Market value and patent citations. Rand Journal of Economics. 1- 49
Hall, B.H., Thoma, G. and Torrisi, S. (2007). Market value of patents and R&D; evidence from EU firms. NBER.
Hall, B., Jaffe, A. B, and Trajtenberg, M. (1998). Patent Citations and Market Value, NBER
Gilroy, B.M., Brandes, W. and Volpert, T. (2003). Economic implications of Intellectual Property Rights for the Biotechnology sector, A comparative analysis of the European – Japanese Situations, http://mpra.ub.uni-muenchen.de/22200/
Narin, F., Noma, E. and Perry, R. (1987). Patents as indicators of corporate technological strength. Research Policy 16, 143-153
Carpenter, M.P, Narin, F. and Woolf, P. (1981). Citation Rates to Technologically Important Patents. World Patent Information. 3 (4) 160-163
Trajtenberg, M. (1990). A penny for Your Quotes: Patent Citations and the Value of Innovations. The RAND Journal of Economics. 21 (1), 172-187
Fallaux, F.J., Hoeben, R.C. Bout, B., Valerio, D. Van der Eb, A.(1995). EP0833934 Packaging Systems of human recombinant adenovirus to be used for gene therapy. https://nl.espacenet.com/EP0833934
Hawk IP. (2012). What is EPODOC and what is DOCDB? http://www.hawkip.com/epodoc
Munari, F., and Oriani, R. (eds.). (2011). The economic valuation of patents: Methods and Applications. Edward Elgar, Cheltenham, UK ; Northampton, p. 169- 199
Blume, S.S. (2013). Medical innovations: Their diffusion, adoption and critical interrogation, Sociology Compass, 7 (9), 726-737, http://doi.org/10.1111/soc4.12062
Rogers, E.M. (2003). The Diffusion of Innovations. MacMillan Publishing C. Inc., New York, p.271- 307
Kers, J.G., Van Burg, E. Stoop, T. and Cornel, M.C. (2014). Trends in Genetic patent applications; the
commercialization of academic intellectual property, European Journal of Human Genetics 1-5,
http://doi.org/10.1038/ejhg.2013.305
OECD (2009). Biotechnology statistics, https://www.oecd.org/sti/42833898.pdf
Kaufman (2012). Start- up act for the States, http://www.kauffman.org/startup act.pdf
Anecdotal data from interviews with Crucell ex- IPR manager and inventors (2014)
Hoeben, R.C. (2001), ‘Van kwaad tot beter’ over virussen, vectoren en gentherapie. Rede uitgesproken bij de aanvaarding van het ambt van hoogleraar in de Genoverdracht aan de Universiteit Leiden (in Dutch)
Pardo, R., and Calvo, F. (2006). Are Europeans really antagonistic to biotech? Nature Biotechnology, 24(4), 393–395. http://doi.org/10.1038/nbt0406-393b
Graff, G.D., Philips, D., Lei, Z. Oh, S. and Nottenburg, C. (2013). Not quite a myriad of gene patents. Nature Biotechnology, 31(5), 404-410, http://doi.org/10.1038/nbt.2568
Editorial (2013). A Victory for Genes, Nature Medicine, 19, 792 http://doi.org/10.1038/nm.3279
Lawrence, S. (2007). Biotech patents still strong, Nature Biotechnology, 25 (12), 1341 http://doi.org/10.1038/nbt1207-1341
